Ocular Therapeut Stock Price, News & Analysis

Ocular Therapeutix, Inc. (NASDAQ: OCUL) will announce its financial results for Q2 2022 on August 8, 2022. The earnings release will be followed by a conference call at 4:30 p.m. ET. Investors can access the live webcast through the company’s website. Ocular Therapeutix focuses on developing innovative eye therapies, including DEXTENZA®, an FDA-approved corticosteroid, and other projects in various clinical trial phases. The company utilizes proprietary bioresorbable hydrogel technology to address ocular conditions.

Aurion Biotech has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer to advance its corneal endothelial cell therapy development. Dr. Goldstein brings extensive experience as a renowned ophthalmologist and biotech executive, previously serving at Ocular Therapeutix (OCUL) and Applied Genetic Technologies Corp (AGTC). His leadership aims to enhance clinical strategy and operations for a treatment addressing corneal edema caused by endothelial dysfunction. This innovative therapy offers significant advantages over traditional corneal transplants, including a more straightforward procedure and a greater supply of cells from donor corneas.

Ocular Therapeutix (NASDAQ:OCUL) announced executive changes to enhance its late-stage ophthalmology product portfolio. Peter K. Kaiser, a prominent ophthalmologist, becomes Chief Medical Advisor for Retina, focusing on clinical strategies for the OTX-TKI program in wet AMD. Rabia Gurses Ozden has been promoted to Chief Medical Officer, effective July 1, 2022, overseeing clinical development. Michael Goldstein transitions to Chief Strategy Advisor post-departure on June 30, 2022. The leadership changes aim to strengthen Ocular's operational capabilities in addressing retinal diseases.

Ocular Therapeutix, a biopharmaceutical company focused on eye therapies, will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 8:00 AM ET in New York. The management team will also hold investor meetings. A live webcast of the presentation will be available on their website for 90 days. Ocular Therapeutix specializes in developing innovative treatments for eye diseases, with products like DEXTENZA® and ongoing clinical trials for several other therapies targeting conditions such as glaucoma and dry eye disease.

Ocular Therapeutix reported Q1 2022 net product revenue of $12.5 million, an increase of 87% year-over-year, driven by DEXTENZA sales. The company projects 2022 annual revenue between $55 million and $60 million, indicating 26% to 38% growth. Underlying business developments include a successful start to their clinical trials for OTX-TKI and OTX-TIC, with the latter's first patient dosed in February, generating a $2 million milestone payment. As of March 31, 2022, cash reserves stand at $145.4 million, expected to fund operations through 2023.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced two scientific presentations at the ASGCT 25th Annual Meeting, highlighting the potential of its hydrogel platform for gene therapy delivery in ophthalmic conditions. Presentations include advancements in controlled release of adeno-associated virus (AAV) and hydrogel implant development. Ocular Therapeutix's leading product, DEXTENZA®, is FDA-approved for ocular inflammation and pain. The company is advancing various clinical trials, including OTX-TKI for wet AMD and OTX-TIC for glaucoma.

Ocular Therapeutix (NASDAQ: OCUL) announced it will report its first quarter financial results for the period ending March 31, 2022, on May 9, 2022. Following the earnings release, the management team will host a conference call at 4:30 PM ET to discuss the financial results and provide a business update. Investors can access the live webcast via the company’s investor section of its website. Ocular Therapeutix focuses on developing innovative therapies for eye diseases, including its FDA-approved product DEXTENZA®.

Ocular Therapeutix (NASDAQ:OCUL) announced its participation in the ARVO Annual Meeting from May 1-4 in Denver, presenting key clinical and pre-clinical data from its eye disease therapies. The company highlighted its hydrogel platform's potential to enhance treatment efficacy and reduce complexities in managing eye diseases. Notable presentations include results on OTX-DED for dry eye disease and OTX-TKI for retinal diseases. The company remains optimistic about advancing its pipeline and addressing unmet medical needs in ophthalmology.

Ocular Therapeutix (NASDAQ:OCUL) announced a strong presence at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The company showcased updates on DEXTENZA, an FDA-approved treatment for ocular inflammation and allergic conjunctivitis, along with the OTX-DED for dry eye disease. Multiple presentations highlighted the efficacy of these therapies, underscoring the potential of Ocular Therapeutix's hydrogel technology to address unmet needs in ophthalmic care. The meeting is set for April 22-26, 2022, in Washington, D.C.